Apnimed acquires rights to sleep apnoea treatment from Desitin

Apnimed Expands Portfolio of Oral Pharmacotherapies for Sleep and Breathing Diseases Through Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor

Apnimed and Shionogi will develop sulthiame within the Shionogi-Apnimed Sleep Science (SASS) Joint Venture for Obstructive Sleep Apnea (OSA) and other sleep-related breathing indications

Apnimed acquires rights to sleep apnoea treatment from Desitin

The acquisition enables Apnimed to advance the therapy through its joint venture (JV) with Japanese pharma company, Shionogi & Co. Desitin Arzneimittel will receive an upfront, future milestone The post Apnimed acquires rights to sleep apnoea treatment from Desitin Arzneimittel appeared first on Pharmaceutical Business review.